You need to enable JavaScript to run this app.
Recon: Regeneron’s Eylea Stumbles as FDA Issues CRL; Amicus Sets $315,000 Price for Fabry Disease Drug
Recon
Ana Mulero
ReconAna Mulero
ReconAna Mulero